Given the high overlap in transcriptional changes observed between CIC-DUX4 depletion and p300 pharmacological degradation, it stands to reason that the anti-tumorigenic effect observed upon p300 depletion may be linked to its functional cooperation with CIC-DUX4 to control a panel of shared target genes involved in tumor growth. This evidence concerns the gene EP300 and neoplasm.